We use cookies for a better user experience. Read our Privacy Policy

I Agree

Metastatic Bone Disease Market

Metastatic Bone Disease Market (Treatment - Medication, Radiation Therapy, Surgical Intervention, and Tumor Ablation Therapy; Origin of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate; End use - Hospitals, Specialty Clinics, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Metastatic Bone Disease Market - An Overview

Metastatic bone disease is a type of cancer that originates in one organ and later spreads to the other parts of the body. The presence of breast cancer is increasing among the elderly female population.

As per the World Health Organization, breast cancer has emerged as the most common form of the disease in developed and developing economies, the reason being improved life expectancy, increase in urbanization, and increasing shift towards western lifestyle.

Among men, prostate cancer is considered to be second most prevalent type of the disease. An increase in the presence of lung, prostate, and breast cancer which then metastasize into the bones is expected to drive demand for metastatic bone cancer treatment.

Few other factors such as strict regulatory policies that assure enhanced product quality, a rise in funding for cancer research, lucrative reimbursement policies, and an increase in cancer awareness programs by governments and other organizations could boost the metastatic bone disease market worldwide.

Fueled by mergers and acquisitions and joint ventures, hospitals are witnessing positive growth. A rise in the number of hospitals is expected to drive the metastatic bone disease market.

In 2017, Europe and North America accounted for a combined total of 60% of the overall share in the metastatic bone disease market. An increase in awareness about cancer and its treatment methods as well as improved healthcare and medical facilities have catalyzed the market in both these regions.

In Asia Pacific countries such as Japan, China, availability of medical devices as well as technological advancements are expected to fuel the metastatic bone disease market. Also in Asia Pacific, the specialty clinics segment is expected to provide substantial growth opportunities. Owing to a rise in the incidence of cancer as well as technological advancements, the metastatic bone disease market could also flourish in Middle East & Africa.

The metastatic bone disease market faces its own set of challenges, as well. High research and development costs, as well as big attrition numbers in the product development cycle could hamper the growth in the metastatic bone disease market. The metastatic bone disease market players adopt organic and inorganic growth strategies to enlarge product offerings, raise customer base, boost geographical presence, and occupy greater market share.

Global Metastatic Bone Disease Market - Snapshot

Metastatic bone disease can be quite agonizing to patients, both emotionally and financially, when they discover that their cancer has reached an advanced stage, thereby diminishing their chance of survival and adding to the treatment costs. According to the American Academy of Orthopedic Surgeons, nearly 50% of new cancer cases detected each year can spread (metastasize) to the skeleton. This leads to an additional treatment burden, with an estimated annual cost of US$ 12 Bn. The global metastatic bone disease market was valued at US$ 12,450.0 Mn in 2017 and is anticipated to reach US$ 24,886.8 Mn by 2026, expanding at a CAGR of 8.1% from 2018 to 2026. Rise in prevalence of cancers such as lung, breast, and prostate that metastasize to bones is anticipated to drive demand for metastatic bone cancer treatment during the forecast period from 2018 to 2026.

Rise in incidence rate of cancer across the world, favorable reimbursement scenario, stringent regulatory policies assuring better product quality, increase in cancer research funding and new drug approvals, and surge in cancer awareness programs by governments and patient support organizations propel the global metastatic bone disease market. However, high attrition rate in product development cycle and high research and development costs are the major factors restraining the global market.

metastatic-bone-disease-market.jpg

The global metastatic bone disease market has been segmented based on treatment, origin of metastasis, end-user, and region. In terms of treatment, the global market has been classified into medication, radiation therapy, surgical intervention, and tumor ablation therapy. The medication segment has been categorized into chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. Based on origin of metastasis, the global metastatic bone disease market has been divided into breast, lung, thyroid, kidney, prostate, and others. In terms of end-user, the global market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. In terms of region, the global metastatic bone disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on treatment, the medication segment dominates the global metastatic bone disease market. Dominance of the segment is attributed to rise in prevalence of metastatic bone cancer and increase in preference among physicians to treat patients primarily with medication. Availability of various medication therapies such as chemotherapy, hormone therapy, and bisphosphonates is a major factor likely to propel the segment from 2018 to 2026. Radiation therapy is considered to be the second most prominent segment of the global metastatic bone disease market. The segment is likely to grow at a rapid pace owing to availability of well-qualified radiologists in developed countries and rise in need of radiation therapy for pain management in metastatic bone cancer.

In terms of origin of metastasis, the breast cancer segment dominated the global metastatic bone disease market in 2017 and the trend is likely to continue during the forecast period. Prevalence of breast cancer is rising due to an aging female population. According to the World Health Organization, breast cancer is the most common cancer in women in both developed and developing countries. This is due to increase in life expectancy, rise in urbanization, and adoption of western lifestyle. Prostate cancer is considered to be the second most prominent segment of the global metastatic bone disease market. Prostate cancer is the second most common cancer in men. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012. According to the American Cancer Society, nearly 1,685,210 new cancer cases were registered in the U.S. in 2016. Therefore, increase in number of cancer patients is expected to drive the prostate cancer segment from 2018 to 2026.

Based on end-user, the hospital segment dominates the global metastatic bone disease market. Hospitals are experiencing strong growth propelled by joint ventures, acquisitions, and provision of one-stop-shop services under one roof for various medical needs. Increase in number of hospitals, improvement in reimbursement policies, and increase in incidence of cancer are expected to drive the global metastatic bone disease market. The specialty clinics segment is likely to present significant opportunities in Asia Pacific.

In terms of region, North America and Europe accounted for combined market share of 60% in 2017. Improved health care infrastructure and rise in awareness about cancer and its treatment augment the market in Europe and North America. Increase in medical tourism is projected to drive the metastatic bone disease market in India. Technological advancements and availability of medical devices in Japan and China are anticipated to propel the market in these countries. Countries in Middle East & Africa are potential markets for metastatic bone disease treatments due to increase in incidence of cancer and advancement in technology.

Major players operating in the global metastatic bone disease market are Amgen, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Bayer AG, Fresenius Kabi AG, BTG plc, Boston Scientific Corporation, and Medtronic. These players adopt organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.

The global metastatic bone disease market has been segmented as follows:

Treatment

  • Medication
    • Chemotherapy
    • Hormone Therapy
    • Bisphosphonates
    • Opiate Therapy
    • Immunotherapy
  • Radiation Therapy
  • Surgical Intervention
  • Tumor Ablation Therapy

Origin of Metastasis

  • Breast
  • Lung
  • Thyroid
  • Kidney
  • Prostate
  • Others

 End-user

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

Provider Type

  • OEM
  • Non-OEM

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa
Metastatic Bone Disease Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metastatic Bone Disease Market

4. Market Overview
     4.1. Introduction
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2016–2026

5. Market Outlook
     5.1. Pipeline Analysis
     5.2. Disease Prevalence & Incidence Rate globally with key countries
     5.3. Reimbursement Scenario, by Region
     5.4. Distribution of procedures global/by region

6. Global Metastatic Bone Disease Market Analysis and Forecasts, by Treatment
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast, by Treatment, 2016–2026
            6.3.1. Medication
                     6.3.1.1. Chemotherapy
                     6.3.1.2. Hormone Therapy
                     6.3.1.3. Bisphosphonates
                     6.3.1.4. Opiate Therapy
                     6.3.1.5. Immunotherapy
            6.3.2. Radiation Therapy
            6.3.3. Surgical Intervention
            6.3.4. Tumor Ablation Therapy
     6.4. Market Attractiveness, by Treatment

7. Global Metastatic Bone Disease Market Analysis and Forecasts, by Origin of Metastasis
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast, by Origin of Metastasis, 2016–2026
            7.3.1. Breast
            7.3.2. Lung
            7.3.3. Thyroid
            7.3.4. Kidney
            7.3.5. Prostate
            7.3.6. Others
     7.4. Market Attractiveness, by Origin of Metastasis

8. Global Metastatic Bone Disease Market Analysis and Forecasts, by End-user
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Market Value Forecast, by End-user, 2016–2026
            8.3.1. Hospitals
            8.3.2. Specialty Clinics
            8.3.3. Ambulatory Surgical Centers
     8.4. Market Attractiveness, by End-user

9. Global Metastatic Bone Disease Market Analysis and Forecasts, by Region
     9.1. Key Findings
     9.2. Market Value Forecast, by Region
            9.2.1. North America
            9.2.2. Europe
            9.2.3. Asia Pacific
            9.2.4. Latin America
            9.2.5. Middle East & Africa
     9.3. Market Attractiveness, by Region

10. North America Metastatic Bone Disease Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Market Value Forecast, by Treatment, 2016–2026
            10.2.1. Medication
                     10.2.1.1. Chemotherapy
                     10.2.1.2. Hormone Therapy
                     10.2.1.3. Bisphosphonates
                     10.2.1.4. Opiate Therapy
                     10.2.1.5. Immunotherapy
            10.2.2. Radiation Therapy
            10.2.3. Surgical Intervention
            10.2.4. Tumor Ablation Therapy
     10.3. Market Value Forecast, by Origin of Metastasis, 2016–2026
            10.3.1. Breast
            10.3.2. Lung
            10.3.3. Thyroid
            10.3.4. Kidney
            10.3.5. Prostate
            10.3.6. Others
     10.4. Market Value Forecast, by End-user, 2016–2026
            10.4.1. Hospitals
            10.4.2. Specialty Clinics
            10.4.3. Ambulatory Surgical Centers
     10.5. Market Value Forecast, by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. Market Attractiveness Analysis
            10.6.1. By Treatment
            10.6.2. By Origin of Metastasis
            10.6.3. By End-user
            10.6.4. By Country

11. Europe Metastatic Bone Disease Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Market Value Forecast, by Treatment, 2016–2026
            11.2.1. Medication
                     11.2.1.1. Chemotherapy
                     11.2.1.2. Hormone Therapy
                     11.2.1.3. Bisphosphonates
                     11.2.1.4. Opiate Therapy
                     11.2.1.5. Immunotherapy
            11.2.2. Radiation Therapy
            11.2.3. Surgical Intervention
            11.2.4. Tumor Ablation Therapy
     11.3. Market Value Forecast, by Origin of Metastasis, 2016–2026
            11.3.1. Breast
            11.3.2. Lung
            11.3.3. Thyroid
            11.3.4. Kidney
            11.3.5. Prostate
            11.3.6. Others
     11.4. Market Value Forecast, by End-user, 2016–2026
            11.4.1. Hospitals
            11.4.2. Specialty Clinics
            11.4.3. Ambulatory Surgical Centers
     11.5. Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6. Market Attractiveness Analysis
            11.6.1. By Treatment
            11.6.2. By Origin of Metastasis
            11.6.3. By End-user
            11.6.4. By Country/Sub-region

12. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Market Value Forecast, by Treatment, 2016–2026
            12.2.1. Medication
                     12.2.1.1. Chemotherapy
                     12.2.1.2. Hormone Therapy
                     12.2.1.3. Bisphosphonates
                     12.2.1.4. Opiate Therapy
                     12.2.1.5. Immunotherapy
            12.2.2. Radiation Therapy
            12.2.3. Surgical Intervention
            12.2.4. Tumor Ablation Therapy
     12.3. Market Value Forecast, by Origin of Metastasis, 2016–2026
            12.3.1. Breast
            12.3.2. Lung
            12.3.3. Thyroid
            12.3.4. Kidney
            12.3.5. Prostate
            12.3.6. Others
     12.4. Market Value Forecast, by End-user, 2016–2026
            12.4.1. Hospitals
            12.4.2. Specialty Clinics
            12.4.3. Ambulatory Surgical Centers
     12.5. Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Market Attractiveness Analysis
            12.6.1. By Treatment
            12.6.2. By Origin of Metastasis
            12.6.3. By End-user
            12.6.4. By Country/Sub-region

13. Latin America Metastatic Bone Disease Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Market Value Forecast, by Treatment, 2016–2026
            13.2.1. Medication
                     13.2.1.1. Chemotherapy
                     13.2.1.2. Hormone Therapy
                     13.2.1.3. Bisphosphonates
                     13.2.1.4. Opiate Therapy
                     13.2.1.5. Immunotherapy
            13.2.2. Radiation Therapy
            13.2.3. Surgical Intervention
            13.2.4. Tumor Ablation Therapy
     13.3. Market Value Forecast, by Origin of Metastasis, 2016–2026
            13.3.1. Breast
            13.3.2. Lung
            13.3.3. Thyroid
            13.3.4. Kidney
            13.3.5. Prostate
            13.3.6. Others
     13.4. Market Value Forecast, by End-user, 2016–2026
            13.4.1. Hospitals
            13.4.2. Specialty Clinics
            13.4.3. Ambulatory Surgical Centers
     13.5. Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Market Attractiveness Analysis
            13.6.1. By Treatment
            13.6.2. By Origin of Metastasis
            13.6.3. By End-user
            13.6.4. By Country/Sub-region

14. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
     14.2. Market Value Forecast, by Treatment, 2016–2026
            14.2.1. Medication
                     14.2.1.1. Chemotherapy
                     14.2.1.2. Hormone Therapy
                     14.2.1.3. Bisphosphonates
                     14.2.1.4. Opiate Therapy
                     14.2.1.5. Immunotherapy
            14.2.2. Radiation Therapy
            14.2.3. Surgical Intervention
            14.2.4. Tumor Ablation Therapy
     14.3. Market Value Forecast, by Origin of Metastasis, 2016–2026
            14.3.1. Breast
            14.3.2. Lung
            14.3.3. Thyroid
            14.3.4. Kidney
            14.3.5. Prostate
            14.3.6. Others
     14.4. Market Value Forecast, by End-user, 2016–2026
            14.4.1. Hospitals
            14.4.2. Specialty Clinics
            14.4.3. Ambulatory Surgical Centers
     14.5. Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
     14.6. Market Attractiveness Analysis
            14.6.1. By Treatment
            14.6.2. By Origin of Metastasis
            14.6.3. By End-user
            14.6.4. By Country/Sub-region

15. Competition Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Market Share Analysis, by Company (2017)
     15.3. Company Profiles
            15.3.1. Amgen, Inc.
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Financial Overview
                     15.3.1.3. Product Portfolio
                     15.3.1.4. SWOT Analysis
                     15.3.1.5. Strategic Overview
            15.3.2. Merck & Co., Inc.
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Financial Overview
                     15.3.2.3. Product Portfolio
                     15.3.2.4. SWOT Analysis
                     15.3.2.5. Strategic Overview
            15.3.3. F. Hoffmann-La Roche Ltd
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Financial Overview
                     15.3.3.3. Product Portfolio
                     15.3.3.4. SWOT Analysis
                     15.3.3.5. Strategic Overview
            15.3.4. Novartis AG
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Financial Overview
                     15.3.4.3. Product Portfolio
                     15.3.4.4. SWOT Analysis
                     15.3.4.5. Strategic Overview
            15.3.5. Eli Lilly and Company
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Financial Overview
                     15.3.5.3. Product Portfolio
                     15.3.5.4. SWOT Analysis
                     15.3.5.5. Strategic Overview
            15.3.6. Bayer AG
                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Financial Overview
                     15.3.6.3. Product Portfolio
                     15.3.6.4. SWOT Analysis
                     15.3.6.5. Strategic Overview
            15.3.7. Fresenius Kabi AG
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Financial Overview
                     15.3.7.3. Product Portfolio
                     15.3.7.4. SWOT Analysis
                     15.3.7.5. Strategic Overview
            15.3.8. BTG plc.
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Financial Overview
                     15.3.8.3. Product Portfolio
                     15.3.8.4. SWOT Analysis
                     15.3.8.5. Strategic Overview
            15.3.9. Boston Scientific Corporation
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Financial Overview
                     15.3.9.3. Product Portfolio
                     15.3.9.4. SWOT Analysis
                     15.3.9.5. Strategic Overview
            15.3.10. Medtronic
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Financial Overview
                     15.3.10.3. Product Portfolio
                     15.3.10.4. SWOT Analysis
                     15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Treatment, 2016–2026
Table 02: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Medication, 2016–2026
Table 03: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Origin of Metastasis, 2016–2026
Table 04: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 05: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
Table 06: North America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Country, 2016–2026
Table 07: North America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Treatment, 2016–2026
Table 08: North America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Medication, 2016–2026
Table 09: North America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Origin of Metastasis, 2016–2026
Table 10: North America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 11: Europe Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Treatment, 2016–2026
Table 13: Europe Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Medication, 2016–2026
Table 14: Europe Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Origin of Metastasis, 2016–2026
Table 15: Europe Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 16: Asia Pacific Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Asia Pacific Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Treatment, 2016–2026
Table 18: Asia Pacific Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Medication, 2016–2026
Table 19: Asia Pacific Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Origin of Metastasis, 2016–2026
Table 20: Asia Pacific Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 21: Latin America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Latin America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Treatment, 2016–2026
Table 23: Latin America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Medication, 2016–2026
Table 24: Latin America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Origin of Metastasis, 2016–2026
Table 25: Latin America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
Table 26: Middle East & Africa Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Country/Sub region, 2016–2026
Table 27: Middle East & Africa Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Treatment, 2016–2026
Table 28: Middle East & Africa Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Medication, 2016–2026
Table 29: Middle East & Africa Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by Origin of Metastasis, 2016–2026
Table 30: Middle East & Africa Metastatic Bone Disease Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026

List of figures

Figure 01: Global Metastatic Bone Disease Market Size (US$ Mn) and Distribution (%), by Region, 2018 and 2026
Figure 02: Global Metastatic Bone Disease Market Value Share, by Origin of Metastasis (2017)
Figure 03: Global Metastatic Bone Disease Market Value Share, by Treatment (2017)
Figure 04: Global Metastatic Bone Disease Market Value Share, by End-user (2017)
Figure 05: Global Metastatic Bone Disease Market Value Share, by Region (2017)
Figure 06: Global Metastatic Bone Disease Market Value (US$ Mn) Forecast, 2016–2026
Figure 07: Global Metastatic Bone Disease Market Value Share (%), by Treatment, 2018 and 2026
Figure 08: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Medication, 2016–2026
Figure 09: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Radiation Therapy, 2016–2026
Figure 10: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Intervention, 2016–2026
Figure 11: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Tumor Ablation Therapy, 2016–2026
Figure 12: Global Metastatic Bone Disease Market Attractiveness, by Treatment, 2017–2025
Figure 13: Global Metastatic Bone Disease Market Value Share (%), by Origin of Metastasis, 2018 and 2026
Figure 14: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Breast Cancer, 2016–2026
Figure 15: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Lung Cancer, 2016–2026
Figure 16: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Thyroid Cancer, 2016–2026
Figure 17: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Kidney Cancer, 2016–2026
Figure 18: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Prostate Cancer, 2016–2026
Figure 19: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 20: Global Metastatic Bone Disease Market Attractiveness, by Origin of Metastasis, 2018–2026
Figure 21: Global Metastatic Bone Disease Market Value Share (%), by End-user, 2018 and 2026
Figure 22: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2016–2026
Figure 23: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialty Clinics, 2016–2026
Figure 24: Global Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2016–2026
Figure 25: Global Metastatic Bone Disease Market Attractiveness, by End-user, 2018–2026
Figure 26: Global Metastatic Bone Disease Market Value Share (%), by Region, 2018 and 2026
Figure 27: Global Metastatic Bone Disease Market Attractiveness, by Region, 2018–2026
Figure 28: North America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 29: North America Metastatic Bone Disease Market Value Share (%), by Country, 2018 and 2026
Figure 30: North America Metastatic Bone Disease Market Attractiveness, by Country, 2018–2026
Figure 31: North America Metastatic Bone Disease Market Value Share (%), by Treatment, 2018 and 2026
Figure 32: North America Metastatic Bone Disease Market Attractiveness, by Treatment, 2018–2026
Figure 33: North America Metastatic Bone Disease Market Value Share (%), by Origin of Metastasis, 2018 and 2026
Figure 34: North America Metastatic Bone Disease Market Attractiveness, by Origin of Metastasis, 2018–2026
Figure 35: North America Metastatic Bone Disease Market Value Share (%), by End-user, 2018 and 2026
Figure 36: North America Metastatic Bone Disease Market Attractiveness, by End-user, 2018–2026
Figure 37: Europe Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 38: Europe Metastatic Bone Disease Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 39: Europe Metastatic Bone Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 40: Europe Metastatic Bone Disease Market Value Share (%), by Treatment, 2018 and 2026
Figure 41: Europe Metastatic Bone Disease Market Attractiveness, by Treatment, 2018–2026
Figure 42: Europe Metastatic Bone Disease Market Value Share (%), by Origin of Metastasis, 2018 and 2026
Figure 43: Europe Metastatic Bone Disease Market Attractiveness, by Origin of Metastasis, 2018–2026
Figure 44: Europe Metastatic Bone Disease Market Value Share (%), by End-user, 2018 and 2026
Figure 45: Europe Metastatic Bone Disease Market Attractiveness, by End-user, 2018–2026
Figure 46: Asia Pacific Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 47: Asia Pacific Metastatic Bone Disease Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 48: Asia Pacific Metastatic Bone Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 49: Asia Pacific Metastatic Bone Disease Market Value Share (%), by Treatment, 2018 and 2026
Figure 50: Asia Pacific Metastatic Bone Disease Market Attractiveness, by Treatment, 2018–2026
Figure 51: Asia Pacific Metastatic Bone Disease Market Value Share (%), by Origin of Metastasis, 2018 and 2026
Figure 52: Asia Pacific Metastatic Bone Disease Market Attractiveness, by Origin of Metastasis, 2018–2026
Figure 53: Asia Pacific Metastatic Bone Disease Market Value Share (%), by End-user, 2018 and 2026
Figure 54: Asia Pacific Metastatic Bone Disease Market Attractiveness, by End-user, 2018–2026
Figure 55: Latin America Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 56: Latin America Metastatic Bone Disease Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 57: Latin America Metastatic Bone Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 58: Latin America Metastatic Bone Disease Market Value Share (%), by Treatment, 2018 and 2026
Figure 59: Latin America Metastatic Bone Disease Market Attractiveness, by Treatment, 2018–2026
Figure 60: Latin America Metastatic Bone Disease Market Value Share (%), by Origin of Metastasis, 2018 and 2026
Figure 61: Latin America Metastatic Bone Disease Market Attractiveness, by Origin of Metastasis, 2018–2026
Figure 62: Latin America Metastatic Bone Disease Market Value Share (%), by End-user, 2018 and 2026
Figure 63: Latin America Metastatic Bone Disease Market Attractiveness, by End-user, 2018–2026
Figure 64: Middle East & Africa Metastatic Bone Disease Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 65: Middle East & Africa Metastatic Bone Disease Market Value Share (%), by Country/Sub-region, 2018 and 2026
Figure 66: Middle East & Africa Metastatic Bone Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 67: Middle East & Africa Metastatic Bone Disease Market Value Share (%), by Treatment, 2018 and 2026
Figure 68: Middle East & Africa Metastatic Bone Disease Market Attractiveness, by Treatment, 2018–2026
Figure 69: Middle East & Africa Metastatic Bone Disease Market Value Share (%), by Origin of Metastasis, 2018 and 2026
Figure 70: Middle East & Africa Metastatic Bone Disease Market Attractiveness, by Origin of Metastasis, 2018–2026
Figure 71: Middle East & Africa Metastatic Bone Disease Market Value Share (%), by End-user, 2018 and 2026
Figure 72: Middle East & Africa Metastatic Bone Disease Market Attractiveness, by End-user, 2018–2026
Figure 73: Market Share of Prominent Key Players: Metastatic Bone Disease Market, 2017

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

233

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved